This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
About 100 peptide drugs have reached clinical approval, with nearly half approved in the past 20 years. The global market may exceed $50 billion.
Why it matters
Peptides sit between small molecules and large biologics, offering a unique balance of specificity, lower toxicity, and simpler manufacturing that drives rapid growth in drug development.
The numbers in context
~100 approved peptide therapeutics; nearly 50% approved in last 20 years; market projected >$50 billion by 2024
How the study worked
Narrative literature review covering therapeutic peptides, parenteral administration routes, and novel delivery systems.
Who was studied
N/A (review of therapeutic peptide field)
What this study cannot tell us
Narrative review without systematic search methodology. Market projections may vary by source. Does not cover every approved peptide individually.
Read the original research
Focus on therapeutic peptides and their delivery.
International journal of pharmaceutics, 675, 125555
Citation
Rosson, E; Lux, F; David, L; Godfrin, Y; Tillement, O; Thomas, E. (2025). Focus on therapeutic peptides and their delivery.. International journal of pharmaceutics, 675, 125555. https://doi.org/10.1016/j.ijpharm.2025.125555